Provided by Tiger Fintech (Singapore) Pte. Ltd.

Nuvation Bio, Inc.

2.09
+0.04001.95%
Post-market: 2.100.0100+0.48%16:57 EDT
Volume:3.37M
Turnover:6.98M
Market Cap:711.15M
PE:-1.03
High:2.12
Open:2.05
Low:2.01
Close:2.05
Loading ...

RBC bullish on Nuvation as royalty deal, non-dilutive financings remove overhang

TIPRANKS
·
03 Mar

BRIEF-Nuvation Bio Secures Up To $250 Million In Non-Dilutive Financings From Sagard Healthcare Partners

Reuters
·
03 Mar

Nuvation Bio Inc: Proceeds From Royalty Interest Financing Expected to Fully Fund U.S. Commercial Launch of Taletrectinib

THOMSON REUTERS
·
03 Mar

Nuvation Bio Secures up to $250 Million in Non-Dilutive Financings From Sagard Healthcare Partners

THOMSON REUTERS
·
03 Mar

Nuvation Bio Secures Up to $250 Million in Non-Dilutive Financings from Sagard Healthcare Partners

Business Wire
·
03 Mar

Nuvation Bio Starts Expanded Access Program for Lung Cancer Drug

MT Newswires Live
·
03 Feb

Nuvation Bio Announces Expanded Access Program in the U.S. for Taletrectinib in Advanced Ros1-Positive Non-Small Cell Lung Cancer

THOMSON REUTERS
·
03 Feb

Nuvation Bio Announces Expanded Access Program in the U.S. for Taletrectinib in Advanced ROS1-positive Non-Small Cell Lung Cancer

Business Wire
·
03 Feb

With 46% stake, Nuvation Bio Inc. (NYSE:NUVB) seems to have captured institutional investors' interest

Simply Wall St.
·
29 Jan

Nuvation Bio Inc : H.c. Wainwright Raises Target Price to $11 From $10

THOMSON REUTERS
·
23 Jan

Nuvation Bio Up Nearly 17%, on Track for Largest Percent Increase Since March 2024 -- Data Talk

Dow Jones
·
08 Jan

Nuvation Bio Price Target Raised to $10.00/Share From $6.00 by RBC Capital

Dow Jones
·
07 Jan

RBC Raises Price Target on Nuvation Bio to $10 From $6, Keeps Outperform, Speculative Risk

MT Newswires Live
·
07 Jan

Nuvation Bio's Taletrectinib Secures Approval in China for Lung Cancer Treatment

MT Newswires Live
·
07 Jan

BRIEF-Nuvation Bio Receives Approval From China's National Medical Products Administration For Taletrectinib For Patients With Advanced ROS1-Positive Non-Small Cell Lung Cancer

Reuters
·
06 Jan

Nuvation Bio Inc - Taletrectinib to Be Marketed in China by Innovent Biologics

THOMSON REUTERS
·
06 Jan

Nuvation Bio Receives Approval From China’s National Medical Products Administration for Taletrectinib for Patients With Advanced Ros1-Positive Non-Small Cell Lung Cancer

THOMSON REUTERS
·
06 Jan

Nuvation Bio Receives Approval from China’s National Medical Products Administration for Taletrectinib for Patients with Advanced ROS1-positive Non-Small Cell Lung Cancer

Business Wire
·
06 Jan

Nuvation Bio Price Target Maintained With a $7.00/Share by HC Wainwright & Co.

Dow Jones
·
06 Jan